Go online to PeerView.com/NUB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in melanoma explore evidence and practical lessons from major studies of adjuvant immunotherapy in melanoma, and provide insights on the future of immune checkpoint blockade in resectable disease. The panel also discusses real-world cases that illustrate how surgeons and oncologists can work together to identify ideal candidates for checkpoint inhibitor therapy and safely integrate immunotherapy into the surgical management of melanoma. Upon completion of this activity, participants should be better able to: Cite current guideline recommendations for the use of adjuvant immunotherapy in resectable melanoma, Summarize updated efficacy findings on the use of immune checkpoint inhibitors as adjuvant or neoadjuvant therapy in resectable melanoma, including high-risk stage III disease, Integrate adjuvant immunotherapy into treatment protocols for eligible patients with resectable stage III melanoma, Manage immune-related and immune-mediated adverse events in patients with melanoma treated with immunotherapy after surgical resection.
View all episodes
